3D Systems Corporation (DDD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with 11% YoY revenue growth and improved EBITDA, driven by robust growth in key sectors like Med Tech and Aerospace & Defense. Despite supply chain disruptions and economic risks, the company achieved positive EBITDA and improved margins. The Q&A section highlighted strategic expansions and product portfolio refreshes, indicating future growth potential. However, cautious guidance due to global volatility is noted. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase in the 2% to 8% range.
Key Financial Performance
Consolidated Revenue $95.5 million, an increase of 11% year-over-year. This growth was driven by Med Tech, Dental, and Aerospace & Defense markets, each achieving meaningful double-digit growth.
Industrial Solutions Revenue $45.4 million, an increase of 1.6% year-over-year. Growth was driven by Aerospace & Defense, which delivered over 20% year-over-year growth, complemented by growth in automotive and semiconductor markets, partially offset by lower demand in certain regional areas due to the conflict in the Middle East.
Healthcare Solutions Revenue $50.1 million, grew 21% year-over-year. Growth was driven by strong performance in Dental and Med Tech, including increased printer and material sales and strong demand for orthopedic medical implants.
Non-GAAP Gross Margin 36.1%, up 6 percentage points from the prior year period. This improvement was due to better manufacturing absorption from higher production and sales volume, favorable consumables mix, improved printer margins, and cost reduction initiatives.
Non-GAAP Operating Expenses $36.6 million, down 35% or $20.1 million from the prior year period. This reduction was due to cost savings initiatives and a transition to a more balanced level of R&D spending.
Adjusted EBITDA Positive $2.1 million, an improvement of $26 million year-over-year. This was driven by higher sales volumes, favorable product mix, and cost savings initiatives, offset by supply chain disruptions, customer business disruptions, and FX and tariff impacts.
Non-GAAP Loss Per Share $0.01, an improvement from a loss of $0.21 in the prior year period.
Total Cash $86.5 million, including $85.1 million in cash and cash equivalents and $1.4 million in restricted cash.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Portfolio: Introduced a refreshed portfolio of new products, including direct metal printing systems and five major polymer printing platforms.
NextDent 300 Jetted Denture Printing System: Achieved significant success with the NextDent 300, including a major deployment by ROE Dental Laboratory, tripling their manufacturing capacity. Expanded market with U.S. and EU regulatory approvals, addressing over 60 million edentulous patients globally.
DMP 350 Metal Printer: Strong sales to medical device customers, driving growth in Med Tech.
Large-Format Metal Printer System: Development supported by a $28 million U.S. government program, ensuring leadership in metal printing.
Med Tech: Double-digit growth in medical parts manufacturing, printer sales, and surgical planning services. Increased demand for titanium and cobalt chrome implants.
Dental: Strong growth in dental material sales, driven by aligners and prosthetic materials. Expanded market for Vertex Dental materials with U.S. regulatory approval.
Aerospace & Defense: Over 20% growth expected in 2026, driven by space, naval, and aero propulsion applications. Expansion of Littleton, Colorado facility to support demand.
Cost Reduction Initiatives: Achieved over $55 million in annualized cost savings, with plans to complete efficiency programs by Q2 2026.
R&D Investments: Focused on refreshing product portfolio and advancing core technologies, transitioning to a balanced level of spending.
Market Focus: Targeted investments in Aerospace & Defense, Med Tech, and Dental markets, leveraging expertise and infrastructure.
Global Expansion: Expanded addressable market for dental solutions with regulatory approvals in the U.S. and EU, with plans for further approvals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The additive manufacturing industry is recovering from a multiyear downturn caused by global economic and geopolitical challenges, which previously led to reduced capital spending by customers.
Customer-Specific Disruptions: Lower-than-expected sales to a key medical customer due to a temporary disruption in their internal operations, though resolved by the end of the quarter, impacted performance.
Regulatory and Market Entry Challenges: Penetrating key growth markets such as Aerospace & Defense, Med Tech, and Dental is challenging due to stringent requirements for quality, precision, reproducibility, and regulatory oversight.
Supply Chain Disruptions: Supply chain disruptions related to the conflict in the Middle East impacted certain regional markets, particularly the jewelry business.
Economic and Currency Risks: Modest foreign exchange (FX) and tariff impacts affected the company's financial performance.
Strategic Execution Risks: The company faces risks in maintaining cost discipline while supporting strategic investments and managing seasonal fluctuations in operating expenses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Additive Manufacturing Industry Recovery: The additive manufacturing industry is emerging from a multiyear downturn caused by global economic and geopolitical challenges. The company expects this recovery to drive growth in the coming years.
Key Growth Markets: The company is focusing on Aerospace & Defense, Med Tech, and Dental markets, which are expected to grow significantly in the years ahead.
Dental Market Expansion: The company has received U.S. and EU regulatory approvals for its denture printing solution, expanding its addressable market to over 60 million patients globally. This represents a multibillion-dollar opportunity.
Aerospace & Defense Growth: The company expects over 20% growth in Aerospace & Defense markets in 2026, driven by applications in space, naval, and aero propulsion systems, as well as unmanned aerial vehicles and precision munitions.
Manufacturing Capacity Expansion: The company is expanding its Littleton, Colorado facility by 80,000 square feet to support the production of metal components, with the grand opening scheduled for late summer 2026.
Revenue Guidance for Q2 2026: The company is guiding Q2 2026 revenue to a range of $93 million to $95 million.
Adjusted EBITDA Guidance for Q2 2026: The company expects an adjusted EBITDA loss in the range of $2 million to $4 million for Q2 2026.
Full-Year Adjusted EBITDA Outlook: The company aims to achieve breakeven adjusted EBITDA or better for the full year 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the key lever to reaccelerate growth in the 3D printing market?
A:Jeffrey Graves highlighted that the company’s decision to maintain R&D spending and refresh its product portfolio was a good bet. The refreshed product line is well-timed with the resurgence of 3D printing. Key growth drivers include the dental sector, Med Tech (especially orthopedics), and Aerospace & Defense, which are embracing 3D printing for its efficiency and ability to work with exotic materials.
Q:What is the Q2 revenue outlook and any notable trends?
A:Jeffrey Graves stated that there were no pull-forwards in Q1, and the uptick in demand was legitimate. Seasonal trends, particularly in healthcare, may cause a slight dip in Q2 due to optional procedures being delayed during vacation periods. The company is taking a measured approach to guidance due to global volatility, including logistics challenges caused by geopolitical issues.
Q:What contributed to the EBITDA profitability in Q1, and what is the outlook for the year?
A:Phyllis Nordstrom explained that stable OpEx and favorable product mix contributed to Q1 EBITDA profitability. Timing of expenses also played a role. The company expects consistent performance throughout the year, driven by product mix and stabilization of OpEx, aiming for adjusted EBITDA breakeven.
Q:What drove the year-over-year growth in the Healthcare business?
A:Jeffrey Graves noted that both personalized healthcare (Med Tech) and dental segments were strong. Med Tech saw double-digit growth driven by faster response times for trauma cases and advancements in oncology treatments. The dental segment benefited from trademark approval for Vertex material in the U.S. and stabilization in teeth straightening and repair markets.
Q:What are the company’s plans for expanding metal additive parts manufacturing?
A:Jeffrey Graves mentioned the addition of an 80,000 square foot facility adjacent to the current one in Littleton. The new facility will focus on industrial part manufacturing, particularly for aerospace applications. It will handle high-end materials like titanium, zirconium, nickel-based alloys, and copper-nickel alloys, with a grand opening expected in late summer.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific impact of Q1 overachievement on the full-year EBITDA outlook. While they mentioned favorable product mix and timing of expenses, the response lacked detailed clarity on how these factors would influence the second half of the year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aerospace Defense
DMP metal
Defense market
Dental Labs
EU
Industrial Solutions
Nordstrom
ROE Dental
Vertex
acceptance
conflict Middle
development
disruption
expansion
flight
increase
investment market
lab dentist
manufacture
market Aerospace
material sale
metal printer
method
part manufacturing
period result
period software
precision
printer material
printer portfolio
printer sale
printing system
product standpoint
propulsion
repair
saving cost
structure investment
titanium
value
DDD Transcript
3D Systems Corporation (DDD) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary indicates strong financial performance with 11% YoY revenue growth and improved EBITDA, driven by robust growth in key sectors like Med Tech and Aerospace & Defense. Despite supply chain disruptions and economic risks, the company achieved positive EBITDA and improved margins. The Q&A section highlighted strategic expansions and product portfolio refreshes, indicating future growth potential. However, cautious guidance due to global volatility is noted. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase in the 2% to 8% range.
3D Systems Corporation (DDD) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed picture: while there's sequential revenue growth and positive developments in sectors like aerospace and defense, the overall year-over-year revenue declined by 9%. The company improved its EBITDA and reduced operating expenses, but gross margins were negatively impacted by a less favorable product mix. The Q&A revealed cautious guidance and some uncertainty, especially around consumer segments. Given these factors, the stock price is likely to remain stable with minor fluctuations, resulting in a neutral sentiment.
3D Systems Corporation (DDD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reflects a negative sentiment due to a significant revenue decline, reduced gross margins, and a net loss. Despite some cost-cutting improvements and new partnerships, the lack of clear guidance on achieving breakeven and the unclear management responses in the Q&A section contribute to investor uncertainty. The positive developments in the dental market and new partnerships are overshadowed by the overall financial performance and market concerns, leading to a likely negative stock price reaction.
3D Systems Corporation (DDD) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture. The company's cost reduction and R&D investments are positive, but the withdrawal of 2025 guidance and uncertainty in capital spending are concerning. The dental market expansion, especially with the NextDent 300, shows promise, yet the aligner business decline and vague profitability timelines weigh negatively. The Q&A reveals cautious optimism, but management's unclear responses on some issues add uncertainty. Overall, the sentiment is neutral with no strong catalysts for a significant stock price move.
DDD Slides
DDD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
